The effectiveness and safety of Chinese Patent Medicines based on syndrome differentiation in patients following percutaneous coronary intervention due to acute coronary syndrome (CPM trial): A nationwide Cohort Study

The incidence of cardiovascular events remains not unusual in patients following percutaneous coronary intervention (PCI) due to acute coronary syndrome (ACS). Chinese patent medicine (CPM) therapy based on syndrome differentiation in addition to conventional medicine (CM) had been expected to furth...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Phytomedicine (Stuttgart) 2023-01, Vol.109, p.154554-154554, Article 154554
Hauptverfasser:	Bai, Ruina, Yang, Qiaoning, Xi, Ruixi, Che, Qianzi, Zhao, Yang, Guo, Ming, Dong, Guoju, Gao, Zhuye, Fu, Changgeng, Wang, Peili, Gu, Feng, Du, Jianpeng, Zhang, Dawu, Duan, Wenhui, Li, Lizhi, Shi, Dazhuo
Format:	Artikel
Sprache:	eng
Schlagworte:	Acute coronary syndrome Acute Coronary Syndrome - drug therapy Acute Coronary Syndrome - etiology Cohort Studies Danlou tablet Guanxin Danshen dripping pill Humans Percutaneous coronary intervention Percutaneous Coronary Intervention - adverse effects Prospective Studies Qishen Yiqi dripping pill Quality of Life Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!